Bluejay Diagnostics (BJDX) Liabilities and Shareholders Equity (2020 - 2026)

Bluejay Diagnostics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 6.07% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $24.0 million (down 22.91% YoY), while the FY2025 annual figure was $7.1 million, up 6.94% from the prior year.
• Liabilities and Shareholders Equity came in at $5.6 million for Q1 2026 at Bluejay Diagnostics, down from $7.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $20.1 million in Q1 2022 to a low of $4.9 million in Q4 2023.
• A 5-year average of $9.4 million and a median of $8.2 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 333.54% in 2022 and sank 63.99% in 2023, its largest moves.
• Bluejay Diagnostics' Liabilities and Shareholders Equity stood at $13.5 million in 2022, then tumbled by 63.99% to $4.9 million in 2023, then soared by 36.74% to $6.7 million in 2024, then increased by 6.94% to $7.1 million in 2025, then dropped by 21.36% to $5.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $5.6 million, $7.1 million, and $4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison